China Resources Boya Bio-pharmaceutical Group Co.,Ltd

SZSE:300294 Stok Raporu

Piyasa değeri: CN¥15.6b

China Resources Boya Bio-pharmaceutical GroupLtd Yönetim

Yönetim kriter kontrolleri 1/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Xiaoming Liang

İcra Kurulu Başkanı

CN¥4.0m

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi3.8yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi3.3yrs
Yönetim Kurulu ortalama görev süresi2.9yrs

Son yönetim güncellemeleri

Recent updates

Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality

Nov 01
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality

A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Oct 01
A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Sep 12
Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

Jul 25
Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

Jun 12
China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Apr 26
China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

Apr 22
Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

Apr 01
China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

Mar 31
What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

CEO

Xiaoming Liang (57 yo)

3.8yrs

Görev süresi

CN¥4,017,400

Tazminat

Mr. Xiaoming Liang serves as Non-Independent Director at Boya Bio-pharmaceutical Group Co., Ltd since February 03, 2021 and also serves as a President. He is a member of the first session of the Biotechnol...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Xiaoming Liang
President & Directorno dataCN¥4.02mVeri yok
Huacheng Liang
VP, CFO2.9yrsCN¥1.69mVeri yok
Bing Chen
Vice President3.8yrsCN¥6.54m0.014%
CN¥ 2.2m
Shousun Ii
Vice President3.8yrsCN¥2.48mVeri yok
Shuanhong Zhang
Vice President2.3yrsCN¥1.27mVeri yok

3.3yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: 300294's management team is considered experienced (3.3 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Xiaoming Liang
President & Director3.8yrsCN¥4.02mVeri yok
Huacheng Liang
VP, CFO2.9yrsCN¥1.69mVeri yok
Shao Shao
Supervisorno dataVeri yokVeri yok
Na Tang
Chairman of Supervisory Board2.9yrsVeri yokVeri yok
Guiling Tan
Non-Employee Representative Supervisor7.7yrsVeri yokVeri yok
Weidong Zhang
Independent Director3.8yrsCN¥200.00kVeri yok
Huasheng Huang
Independent Director3.8yrsCN¥200.00kVeri yok
Li Zhao
Independent Director3.8yrsCN¥200.00kVeri yok
Kai Qiu
Chairman of the Board1.1yrsVeri yokVeri yok
Jinfeng Shen
Director1.1yrsVeri yokVeri yok
Jinni Sun
Directorless than a yearVeri yokVeri yok
Yuxuan Pan
Directorless than a yearVeri yokVeri yok

2.9yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300294's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.